Brentuximab Vedotin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Brentuximab Vedotin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
211
Registered trials
414
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Brentuximab Vedotin can convert its Antibody drug conjugate (ADC) profile and CD30 x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Brentuximab Vedotin (query alias: Brentuximab Vedotin) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); CD30 x Tubulin; CD30 inhibitors, Tubulin inhibitors |
| Highest global status | Approved |
| Originator | Seagen, Inc. |
| Active developers | Seagen, Inc., Takeda Pharma A/S, Takeda Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07572123 | Phase 2/3 | Not yet recruiting | 374 | Progression-free survival (PFS) (Standard risk cohort) |
| NCT07275216 | Phase 2 | Recruiting | 23 | Complete metabolic response (CMR) to pembrolizumab and gemcitabine (P-G) |
| ChiCTR2600122977 | Phase 1 | Recruiting | 15 | Overall response rate (ORR) after 2 cycles of chemotherapy |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase 1/2; n=65; evaluation: not stated. Reported fields: -; -; -
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Phase 2; n=52; evaluation: not stated. Reported fields: -; Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma = 96.2 percentage of participants (95% Confidence Interval, 86.8 - 99.5); -
BRENTUXIMAB VEDOTIN IN SEVERE SYSTEMIC SCLEROSIS: DATA ON LONG-TERM FOLLOW-UP AND RETREATMENT
Not Applicable; n=10; evaluation: Positive. Reported fields: mRSS(104 week) = 5 patients had mRSS worsening (≥6 points) and 5 remained relatively stable
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Brentuximab Vedotin addresses Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-03-13 | Pfizer Completes Acquisition of Seagen | Approved | US$43,000.0M stated total |
| 2009-12-14 | Seattle Genetics and Millennium: the Takeda Oncology company announce strategic collaboration for novel late-stage lymphoma program Brentuximab Vedotin (SGN-35) | Phase 2 | US$60.0M upfront; US$305.0M milestones; US$365.0M stated total |
| 1998-03-01 | Seagen obtained rights to some of its technologies and product candidates, portions of which are exclusive, through a license agreement with Bristol-Myers Squibb | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
